Practice Resources
Browse our practice resources to help you accurately assess and treat your patients with canine osteoarthritis (OA).
Get Up to Speed with Galliprant® (grapiprant tablets)
Expand your knowledge of Galliprant treatment offline with our downloadable resources.
Galliprant Product Label
See full prescribing information in the product label.
COAST Publication
Learn about an innovative staging system for canine OA, developed by a group of international experts in veterinary surgery and pain management.
Galliprant Factsheet
Review this factsheet to help understand OA, the importance of treating early and Galliprant as part of effective pain management.
Interactive COAST Form
Download this interactive version of the staging tool, which will take you through the process one step at a time and automatically calculate the COAST stage of osteoarthritis (OA) for your canine patients.
Printable COAST Form
Print this downloadable version of the staging tool to walk through the process one step at a time and calculate the COAST stage of OA for your canine patients.
Interactive LOAD Form
Download this interactive version of the LOAD questionnaire for dog owners to fill out while in the clinic. For your convenience, the final LOAD score is automatically calculated. Please note this document is not compatible with mobile devices.
Printable LOAD Form
Print this downloadable LOAD questionnaire for dog owners to fill out in the clinic or at home.
Indication
Galliprant is an NSAID that controls pain and inflammation associated with osteoarthritis in dogs.
Important Safety Information
Not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If Galliprant is used long term, appropriate monitoring is recommended. Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. Click here for full prescribing information.
Contact your Elanco or distributor representative, or call Elanco (1-888-545-5973) to discover how you can incorporate Galliprant into your canine OA protocol today.
© 2022 Elanco or its affiliates. Galliprant, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.
PM-US-19-1929(2)